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Abstract
Background: Malaria still remains a life-threatening disease worldwide causing between 190 and 311 million cases
of malaria in 2008. Due to increased resistance to sulphadoxine-pyrimethamine (SP), the Ministry of Health in
Malawi, as in many sub-Saharan African countries, changed the malaria treatment policy to use artemisinin-based
combination therapy (ACT). In order to optimize the correct use of this drug, and protect against the development
of the parasite’s resistance, it is important to assess the knowledge and practices of medical practitioners on the
use of ACT and its impact on adherence to new treatment policy guidelines.
Methods: A cross-sectional survey was conducted to assess the knowledge and perceptions of Malawian medical
doctors and pharmacists on the use of ACT and the drivers of treatment choice and clinical treatment decisions.
Medical doctors and pharmacists who are involved in managing malaria patients in Malawi were recruited and a
self-administered questionnaire was used to obtain information on socio-demographic characteristics of the study
participants, knowledge on ACT, source of information on ACT and methods used to decide on the treatment of
patients with malaria.
Results: Most of the participants (95.7%) know at least one form of ACT, 67.4% reported that different forms of
ACT have different characteristics, 77.3% reported that there are special formulations for children. The most
commonly mentioned ACT was artemether-lumefantrine (AL), by 94.6% of the participants and 75.0% of the
participants indicated that they prefer to prescribe AL. 73.9% of participants had ever received information on ACT.
However, only 31.5% had received training on management of malaria using ACT. There were 71.7% respondents
who had heard of ACT causing side effects. Only 25.0% of the participants had received training on how to report
SAEs.
Conclusion: It was found that most of the participants know about ACT and treatment guidelines for malaria.
However, most of the participants have not received any training on how to use ACT and how to report adverse
effects arising from the use of ACT. There is need for more training of health care professionals to ensure correct
and effective use of ACT.
Background
Malaria still remains a major public health problem
worldwide. It is estimated that between 190 and 311
million cases of malaria occurred in 2008 (1). Malaria
and its complications are controlled by preventing infec-
tion, prompt diagnosis and effective treatment [1,2].
Due to the widespread resistance to chloroquine and
sulphadoxine-pyrimethamine (SP), the World Health
Organization (WHO) currently recommends the use of
artemisinin-based combination therapy (ACT) for the
treatment of Plasmodium falciparum infection, and
Plasmodium vivax infection resistant to chloroquine.
Artemisinin derivatives rapidly decrease parasite density
and gametocyte levels in treated patients, and, therefore,
greatly reduce the level of infectiousness, and transmis-
sion of resistant strains [3]. There are several forms of
ACT that are currently being used for treatment of
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nate-mefloquine, artesunate-amodiaquine, artesunate-
sulphadoxine-pyrimethamine (SP), and dihydroartemisi-
nin-piperaquine (DHA-PQ)[4].
Currently, most countries in sub-Saharan Africa have
switched to using ACT as the first- and/or second-line
of treatment of malaria [5]. The uptake of the new treat-
ment policies has faced several challenges including
inadequate diagnostic facilities and inappropriate use of
drugs [6]. To ensure that new treatment guidelines and
recommendations are effectively utilized, a systematic
involvement of all the key stakeholders (including pol-
icy-makers, media, practitioners and the general public)
at all stages of implementation is crucial [7]. Only a few
studies have examined the impact of knowledge and
practices of medical practitioners on the use of ACT
and adherence to new treatment policy guidelines in
countries that have adopted the use of ACT. One study
found that despite high level of awareness of a new
malaria treatment policy, a significant percentage of
clinicians (76.2%) reported continued use of SP [8].
Another study found that there was lack of involvement
of the pharmaceutical personnel working in the private
pharmacies, from the preparation of new malaria treat-
ment guidelines to their implementation, and this con-
tributed to their poor knowledge and skill on how to
correctly dispense the medicines [9].
Three years have now passed since Malawi changed
the treatment policy to ACT. The first-line treatment
for uncomplicated malaria is AL and the second-line is
amodiaquine-artesunate. Recommended treatment for
severe malaria is quinine. For pregnant women, AL is
used for treatment of uncomplicated malaria in the sec-
ond and third trimester whilst quinine is used for treat-
ment of uncomplicated malaria in the first trimester of
pregnancy and also for severe malaria in all trimesters.
Accordingly, there is need to assess the knowledge and
practices of doctors and pharmacists as they are key
health care personnel influencing the dispensing of anti-
malarials. This has an impact on the risk for develop-
ment drug resistance if proper guidelines are not fol-
lowed. This information would be useful for guiding
discussions to expand access to, affordability and appro-
priate use of ACT, notably in a period of increasing
therapeutic options, and a shift to confirmed case man-
agement of malaria.
Methods
This was a cross-sectional survey that was conducted in
Malawi between April and September 2010. Using a list
obtained from the Malawi Medical Council and the Phar-
macy Medicines and Poisons Board (PMPB), a random
sample of medical doctors and pharmacists who manage
patients with malaria or dispense antimalarials in the
public and private sector were recruited. Doctors and
pharmacists who were not involved in managing malaria
patients or dispensing anti-malarials and participants
w h od i dn o tp r o v i d ec o n s e n tw e r ee x c l u d e df r o mt h e
study. The required sample size was 112 with 80% power,
assuming that 185 doctors and pharmacists are registered
to practice in Malawi, 80% of these manage patients with
malaria and that 70% had ever heard of ACT. At the time
the study was conducted, there were 205 registered doc-
tor and pharmacists, and responses were obtained from
92 participants giving a 99% power (posthoc) for the
study. The study participants were notified about the
objectives of the study via email, a phone call or in per-
s o na ta n yo p p o r t u n et i m ea n dw e r ea s k e df o rv e r b a l
consent to participate in the study. After providing con-
sent, the participants were given the questionnaire in per-
son or via email or post (Additional file 1). Data collected
included socio-demographic characteristics of the study
participants, knowledge on ACT, source of information
on ACT and methods used to decide on the treatment of
patients with malaria. The participants either emailed
back the questionnaire or it was collected from their
work place or at relevant meetings. To ensure confidenti-
ality, each questionnaire was assigned a study number
and the participants were not required to fill in their
name to anonymize the data. Where identifying informa-
tion was indicated on the questionnaire, it was removed
during data entry and a link file was used to identify the
participants. Participants who did not return the ques-
tionnaire were contacted by phone or email at least three
times and if there was still no response, an attempt was
made to visit them at their work place to obtain the ques-
tionnaire. This study was approved by the College of
Medicine Research and Ethics Committee; protocol num-
ber P.05/10/941.
The data was double-entered into Microsoft Excel,
cleaned and analysed using STATA version 10. Descrip-
tive analysis of categorical data was done using frequen-
cies and percentages while continuous data were
described using means, standard deviations, medians
and interquartile ranges. The percentages were calcu-
lated based on the total number of responders per ques-
tion. Comparison of categorical data was performed
using the Pearson Chi-square test or Fisher’s Exact test
if necessary. Responses to open ended questions were
grouped into common themes.
Results
Demographic characteristics of study participants
Data was obtained from 44.9% (92/205) of the doctors
and pharmacists listed on the Malawi Medical Council
and PMPB register. Most of the respondents were male
(62.0%, n = 57/92), general practitioners (72.2%, n = 65/
90) with a median age of 32 years (Interquartile range
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pants had been working in their profession was 3 years
(IQR 1-9 years). Further information on the characteris-
tics of the respondents is shown in Table 1.
Malaria diagnosis practices and knowledge on malaria
treatment guidelines
Most respondents reported that they diagnosed malaria
using microscopy (73.1%, n = 60/82), some used both
Rapid Diagnostic Tests (RDTs) and microscopy (25.6%,
n = 21/82). Only 1.2% (n = 1/82) reported relying on
RDTs alone for diagnosis. Almost all of the respondents
(84.1%, n = 69/82) also used clinical symptoms when
diagnosing malaria. Factors contributing to the choice of
test used for malaria diagnosis included availability of
tests (49.0%, n = 24/60), patient symptoms (26.5%, n =
13/60) and cost of the test (10.2%, n = 5/60).
Most the participants knew the first line treatment for
uncomplicated malaria [children (94.6%, n = 87/92) and
adults (96.7% (n = 89/92)] and for severe malaria [children
(96.7% (n = 89/92) and adults (97.8% (n = 90/92)]. How-
ever, not many participants knew the treatment guidelines
for pregnant women with only 40.0% (n = 34/85) indicating
the correct treatment guidelines for uncomplicated malaria
and 82.6% (n = 76/92) for severe malaria. Most of the parti-
cipants [79.7% (59/74)] reported that they used treatment
guidelines when managing patients with malaria.
Malaria treatment practices
Most of the participants (70.7%, n = 65/92) reported
that the type of ACT that they prescribe varies
depending mainly on the age of the patient (72.3%) and
the clinical picture of the patient (64.6%). Most of the
participants also reported that they preferred to pre-
scribe AL (75%, n = 69/92) followed by artesunate-SP
(8.7%, n = 8/92), artesunate-amodiaquine (5.4%, n = 5/
92), and DHA-PQ (1.1%, n = 1/92). Reasons for pre-
scription preferences included following government
treatment policy (79.7%, n = 55/69), therapeutic efficacy
(55.1%, n = 38/69) and cost of the drugs (36.2%, n =
25/69).
Knowledge on artemisinin combination therapy
Almost all of the participants (97.8%, n = 90/92) had
heard about ACT and most were able to mention at least
one type of ACT: one type of ACT (40.2%, n = 37/92),
two types of ACT (29.4%, n = 27/92), three types of ACT
(13.0%, n = 12/92), four types of ACT (10.9%, n = 10/92)
and five types of ACT (2.2%, n = 2/92). However, some
of the participants (40.2%, n = 37/92) did not differen-
tiate between a trade and a generic name and, therefore,
repeated the names of ACT they know. Pharmacists/
Pharmacy Technicians/Pharmacy Assistants were more
likely to mention three or more types of ACT compared
with doctors/medical specialists, p < 0.001. Most of the
participants (92.4%, n = 85/92) indicated that AL is avail-
able in Malawi and almost all participants (93.5%, n = 86/
92) have prescribed AL (Table 2).
Most of the participants (67.4%, n = 62/92) indicated
that different types of ACT have differences in cost
(75.8%, n = 47/62), appearance (64.5%, n = 40/62) and
mode of action (43.6%, n = 27/62), (Table 3). There was
no significant difference in the responses between medi-
cal doctors and pharmacists, p > 0.05.
Most participants (70.7%, n = 65/92) indicated that
there are types of ACT spe-cifically manufactured for
children. They noted that a paediatric formulation is
available for AL (89.2%, n = 58/65), artesunate-amodia-
quine (10.8%, n = 7/65), artesunate-SP (7.7%, n = 5/65),
dihydroartemether/piperidyl-quinine (1.5%, n = 1/65)
and pyronaridine-artesunate (1.5%, n = 1/65). The parti-
cipants also indicated that there are different types of
packaging of the children’s medication including blister
packs 6.6% (n = 4/61) and sachets 1.6% (n = 1/61) and
formulations including tablets, powder and suspension
(Table 3).
Side effects of ACT and pharmacovigilance
Most of the participants (71.7%, n = 66/92) reported
that they had heard of ACT causing side effects. Most
of the side effects reported were for AL and these
included nausea (32.8%), headache (25.0%) and vomiting
(21.9%) (Table 4). The only other type of ACT that was
reported to cause side effects was DHA-PQ (skin rashes)
and artesunate-SP (nausea, vomiting, diarrhoea, Steven-
Table 1 Demographic characteristics of the study
participants
Characteristic N = 92
Age, median (IQR), years 32 (26-40)
Male (%) 57 (62.0)
Primary profession (%)
General practitioner 65 (72.2)
Medical specialist 17: (18.9)
Pharmacist 5 (5.6)
Pharmacy Technician 2 (2.2)
Pharmacy Assistant 1 (1.1)
Work sector (%)
Private 28 (30.4)
Public 59 (64.1)
Non-governmental organization 5 (5.4)
Location of practice (%)
Urban 76 (82.6)
Rural 16 (17.4)
Duration of practicing, median (IQR), years 3 (1-9)
Number of patients seen per week, median (IQR) 140 (70-210)
Number of malaria patients seen per week, median (IQR) 35 (10-70)
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pants (77.2%, n = 71/92) indicated that they never had a
severe adverse event (SAE) reported as a result of
patients taking ACT. However, a few participants had
received SAE reports ranging from 1-10 over a period of
1 to 12 months. Nearly 40% of the participants (38.0%,
n = 35/92) knew where to report SAEs, while only
25.0% (n = 23/92) had received training on how to
report SAEs.
Source of information on ACT
Most of the participants (73.9%, n = 68/92) reported
that they have ever received information on ACT.
Participants reported multiple sources of information
including books (50.0%, n = 34/68), peer-reviewed jour-
nals (45.6%, n = 31/68), drug formulary (51.5%, n = 35/
68), government documents (64.7%, n = 44/68), from
the internet (17.6%, n = 12/68), brochures (2.9%, n = 2/
68), scientific meetings (4.4%, n = 3/68) and from collea-
gues 1.5% (n = 1/68). Only 32 (34.8%) of the partici-
pants had received information on ACT from
pharmaceutical companies, including Novartis (40.6%, n
= 13/32), Dafra (6.3%, n = 2/32), GlaxoSmithKline
(GSK) (6.3%, n = 2/32) and Intermed Pharmaceutical
(6.3%, n = 2/32), Medinomics (3.1%, n = 1/32). There
was one participant (3.1%) who obtained information
Table 3 Knowledge on difference in ACTs and types of
formulations
Characteristic N (%)
Type of formulation or packaging*
Tablet 23 (37.7)
Syrup 16 (26.2)
Dispersable 9 (14.8)
Powder 6 (9.8)
Suspension 4 (6.6)
Characteristics of ACTs**
Price 47 (75.8)
Appearance 40 (64.5)
Therapeutic efficacy 38 (61.3)
Mode of action 27 (43.6)
Quality 26 (41.9)
Individuals who can use them 25 (40.3)
Safety 18 (29.0)
Ease of use 3 (4.8)
Dosage 3 (4.8)
Manufacturer 2 (3.2)
Side effect profile 1(1.6)
*This question was for 62 respondents who indicated that there are differences in
paediatric formulations of ACTs
**There were 62 doctors who indicated that there are differences in the
characteristics of ACTs
Table 4 Reported side of effects of taking Artemether-
Lumefantrine
Side effect N* (%)
Nausea 21 (32.8)
Headache 16 (25.0)
Vomiting 14 (21.9)
Abdominal pain 11(17.2)
Skin Rash/urticaria/pruritus 9 (14.1)
Lethargy/Myalgia/Arthralgia 9 (14.1)
Dizziness 7 (10.9)
Diarrhoea 8 (12.5)
Cardiac arrhythmias 5 (7.8)
Anorexia 4 (6.3)
Sleep disorders 4 (6.3)
Elevated liver enzymes/hepatotoxicity 3 (4.7)
Fetotoxicity 3 (4.7)
Palpitations 4 (6.3)
Weakness/fatigue 2 (3.1)
Indigestion 2 (3.1)
Anaemia 1 (1.6)
Jaundice 1 (1.6)
Oral sores 1 (1.6)
Hallucinations 1 (1.6)
Renal toxicity 1 (1.6)
* This only includes 64 respondents who had heard of side effects of ACTs
Table 2 Knowledge of types of ACTs and availability in Malawi
Known Available Dispensed ACTs
ACTs, n (%) ACTs, n (%) ACTs, n (%)
Artemether- Lumefantrine 87 (94.6) 85 (92.4) 86 (93.5)
Artesunate Amodiaquine 35 (38.0) 31 (33.7) 10 (10.9)
Artemisinin-SP 18 (19.6) 18 (19.6) 14 (15.2)
Dihydroartemisinin-piperaquine 13 (14.1) 6 (6.5) 5 (5.4)
Artesunate-Mefloquine 9 (9.8) 4 (4.3) 2 (2.2)
Pyronaridine-Artesunate† 6 (6.5) 0 0
Dihydroartemether/Piperidyl Quinine 4 (4.3) 3 (3.3) 2 (2.2)
Piperaquine-Artesunate 2 (2.2) 0 0
Chloroproguanil-Dapsone Artesunate 2 (2.2) 0 0
†This product is still in development and is therefore correctly indicated as not being available and not yet being prescribed
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private-partnership organization that develops new anti-
malarial medicines in collaboration with pharmaceutical
companies for public health aims. Furthermore, only 29
(31.5%) of the participants have received training on
management of malaria using ACT mostly from the
Ministry of Health (MoH) (55.2%, n = 16/29) or the
National Malaria Control Programme (10.3%, n = 3/29).
Discussion
This study was conducted to assess the knowledge of
health care professionals on ACT and their treatment
practices using ACT. Most of the participants (95.7%)
knew at least one type of ACT, 67.4% reported that dif-
ferent forms of ACT have different characteristics,
77.3% indicated that there are special formulations for
children and 71.1% had heard of side effects caused by
ACT. Although most of the participants had heard
about ACT, 40.2% were not able to differentiate between
trade and generic names of the drugs. As such, they
listed a drug several times using different trade names
assuming that they were different drugs. Furthermore,
only 13.1% of the participants were able to list at least
four types of ACT. Further training or providing infor-
mation materials might be useful to help clarify the dif-
ference between brand names and generic or molecular
names i.e. International Nonproprietary Names (INN) of
ACT.
AL was the most commonly mentioned ACT by 94.6%
of the participants. Other commonly mentioned ACT
included artesunate-amodiaquine, artemisinin-SP and
DHA-PQ. AL and artesunate-amodiaquine are the first-
and second-line treatment in Malawi, respectively. Phar-
macists were significantly more likely to mention at
least three types of ACT compared with doctors. This
could be because pharmacists manage drugs on a more
regular basis than doctors. Most of the participants
(67.4%) indicated that different types of ACT are differ-
ent in terms of appearance, mode of action and thera-
peutic efficacy and 77.3% indicated that there are types
of ACT that are specially formulated for children, which
are packaged as tablets, syrup, powder, blister packs or
suspension. Studies have shown that paediatric formula-
tions are easier to administer to children and are better
tolerated than adult formulations [10]. It is, therefore,
encouraging to note that most of the participants know
these formulations to ensure effective management chil-
dren with malaria. However, it should be noted that
artemisinin-based treatments in syrup or powder form
may be less stable and are, therefore, not recommended
by WHO as appropriate formulations for this class.
Only a few (31.5%) participants received training on
how to manage patients using ACT. Studies in other
countries have also found that few health care
professionals receive training after changes in treatment
policy and this has an impact on prescription practices
[11,12]. Most of the participants obtained their informa-
tion on ACT from books, peer reviewed journals and
the drug formulary. Despite the low coverage in train-
ing, most of the participants (75.0%) indicated that they
prefer to prescribe AL following government policy
recommendations. It appears therefore that most of the
health care professionals are following government
treatment guidelines. Other reasons for prescription pre-
ferences included therapeutic efficacy, availability of
drugs, possibility of use in children, price, appearance,
confidence in the quality of manufacturer and treatment
regimen; some of these factors have also been cited in
other previous studies [13,14].
T h eA C Tt h a tw a sm o s tc o m m o n l yr e p o r t e dt oc a u s e
side effects was AL. This could be attributed to the fact
that AL is used more frequently in Malawi than any of
the other types of ACT. The other types of ACT men-
tioned to cause side effects were DHA-PQ and artesu-
nate-SP. It is important to note that some of the side
effects that were reported such as headache, nausea,
vomiting are also symptoms of malaria, and therefore
might not be as a result of taking the drugs. Surpris-
ingly, there was no mention of side effects caused by
amodiaquine-artesunate, the second-line treatment for
malaria in Malawi. Most of the health care professionals
reported that they do not know how to report SAEs and
therefore the government should consider providing
more training on SAEs reporting and management as
this has an impact on drug adherence.
Most of the participants knew the treatment guide-
lines for uncomplicated and severe malaria in children,
non-pregnant adults and treatment of complicated
malaria in pregnant women. However, only 40.0% of the
participants knew the correct treatment guidelines for
uncomplicated malaria in pregnant women. Pregnant
women are one of the groups at most risk for malaria
and its complications [15]. Additionally, since Malawi is
a high malaria transmission area, most of the pregnant
women present with asymptomatic malaria or a mild ill-
ness [16]. Therefore, with such low levels of knowledge
on treatment guidelines, most pregnant women with
uncomplicated would receive the wrong treatment.
Most of the doctors (73.1%) were still using micro-
scopy to diagnose malaria. There were a few doctors
who were using either RDTs only (1.2%) or RDTs and
microscopy (25.6%) to diagnose malaria. Almost all of
the doctors (84.1%) were also using clinical symptoms
to diagnose malaria. The decision on which test to use
depended on the availability of the test, costs and
patient symptoms. RDTs have just been introduced in
Malawi and, therefore, might not be readily available for
use in all health facilities, clinics or other facilities. In
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tively based on symptoms due to lack of equipment and
microscopy expertise [17]. It is good to note that on the
contrary, most of the doctors in this study diagnose
malaria using a diagnostic test (microscopy or RDTs) in
addition to symptoms.
The study had the following limitations. Not all parti-
cipants who were approached gave responses and they
might have had different characteristics from the indivi-
duals who participated in this study. Second, the ques-
tionnaires were self-administered and some participants
did not fill in all the required information. Third, the
study recruited medical doctors and pharmacists only
and therefore the results cannot be generalized to other
cadres like clinical officers, nurses and community
health workers who are also involved in managing
patients with malaria. Therei sn e e dt oc o n d u c tf u r t h e r
studies to assess if the level of knowledge and treatment
practices would be different in the other cadres not
included in this study. However, despite these limita-
tions, important information was obtained on the
knowledge and practices of health professionals in
Malawi on ACT.
Conclusion
In conclusion, most of the health care professionals have
h e a r da b o u tA C Ta n dt h e yk n o wt h et r e a t m e n tg u i d e -
lines for malaria. However, only a few health care pro-
fessionals have received training on how to use ACT
and how to report SAEs resulting from ACT. It is
important for the MOH to continue engaging health
care professional to ensure correct use of ACT for
proper management of malaria patients and to reduce
the risk of development of resistance to ACT.
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